Using AI to embrace patient heterogeneity

Written By Yolandi Stanek

Auransa’s AI-driven prediction of drug candidates and corresponding patient responders increases the chances of clinical trial success.

Yolandi Stanek https://helloyo.com
Previous

Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses
Next

Development of the digital arthritis index for rheumatoid arthritis